ScreenerHero

SPRC SciSparc Ltd.

NAS · US · Healthcare · Biotechnology · scisparc.com
4.640USD+7.16%Mkt Cap: 107.06M $P/E: 0.02

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agit…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap107.06M USD
Enterprise Value7.97M USD
Revenue (TTM)1.14M USD
Gross Profit631.00K USD
Net Income (TTM)-12.18M USD
Revenue/Share3.06 USD
Last Price4.640 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees3
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.02
P/E (Forward)—
PEG—
EV/EBITDA-0.63
EV/Revenue6.99
P/S87.64
P/B0.37
EPS (TTM)248.24
EPS (Forward)—
52W Range
2.9803% of range63.90
52W High63.90 USD
52W Low2.980 USD
Profitability
Gross Margin73.71%
Oper. Margin-1720.78%
EBITDA Margin0.00%
Profit Margin-1422.78%
ROE-287.31%
ROA-159.79%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.14M USD
CapEx (TTM)—
FCF Margin-594.75%
FCF Yield-6.33%
Net Debt-1.76M USD
Net Debt/EBITDA0.14
Balance Sheet
Debt/Equity0.09
Current Ratio0.87
Quick Ratio0.79
Book Value/Sh11.60 USD
Cash/Share8.01 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:9
Split DateMar 4, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.23.07M
Float534.79K
Insiders0.00%
Institutions9.25%
Short Interest
Short Ratio0.3d
Short % Float1.89%
Short % Out.1.89%
Shares Short10.99K
Short (prev mo.)17.21K
Technical
SMA 505.885 (-21.2%)
SMA 2006.583 (-29.5%)
Beta—
S&P 52W Chg15.78%
Avg Vol (30d)33.57K
Avg Vol (10d)26.80K
Technical Indicators
RSI (14)42.2
MACD-0.3668
MACD Signal-0.3699
MACD Hist.+0.0031
BB Upper5.428 USD
BB Middle4.833 USD
BB Lower4.239 USD
BB Width24.60%
ATR (14)0.4298 USD
Vol Ratio (20d)1.99x